Evidence map›Paper›PMID 36923535›Full record

ArticleTheranostics2023

First

Ludger Starke, Jason M Millward, Christian Prinz, Fatima Sherazi, Helmar Waiczies, Christoph Lippert, Marc Nazaré, Friedemann Paul, Thoralf Niendorf, Sonia Waiczies

Open access · goldFull text read
In one paragraph

Article in Theranostics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Ludger StarkeMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Ultrahigh Field Facility, Berlin, Germany.
Jason M MillwardMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Ultrahigh Field Facility, Berlin, Germany.
Christian PrinzMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Ultrahigh Field Facility, Berlin, Germany.
Fatima SheraziMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Ultrahigh Field Facility, Berlin, Germany.
Helmar WaicziesMRI.TOOLS GmbH, Berlin, Germany.
Christoph LippertHasso Plattner Institute for Digital Engineering, University of Potsdam, Germany.
Marc NazaréMedicinal Chemistry, Leibniz-Institut fϋr Molekulare Pharmakologie (FMP), Berlin, Germany.
Friedemann PaulExperimental and Clinical Research Center, a joint cooperation between the Charité Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Thoralf NiendorfMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Ultrahigh Field Facility, Berlin, Germany.
Sonia WaicziesMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Ultrahigh Field Facility, Berlin, Germany.
Max Delbrück Center · DEFernhochschule – The Mobile University · DEFreie Universität Berlin · DEHasso Plattner Institute · DELeibniz-Forschungsinstitut für Molekulare Pharmakologie · DEScientific Research Institute of Experimental and Clinical Medicine · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Theranostic imaging methods could greatly enhance our understanding of the distribution of CNS-acting drugs in individual patients. Fluorine-19 magnetic resonance imaging (

Indexed as

Fluorine-19 Magnetic Resonance ImagingMultiple SclerosisMultiple Sclerosis, Chronic ProgressiveAnimalsAzetidinesBenzyl CompoundsMagnetic Resonance ImagingMicePharmaceutical PreparationsSphingosine-1-Phosphate ReceptorsAzetidinesBenzyl CompoundsPharmaceutical PreparationssiponimodSphingosine-1-Phosphate ReceptorsFluorineMolecular ImagingMRIMultiple SclerosisSiponimod

Identifiers

PMID36923535
PMCPMC10008739
OpenAlexW4320489156

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read72
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.